PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer – Part 3 of 3
There was such evidence in a Canadian trial, Ross acknowledged, but “in the Canadian ruminate on there were men with a lot more cancer than we would be comfortable following. We only select men with very little cancer”.
So it is too early to give up on PSA kinetics as a method of determining who should be treated. But it is only one of the tools that should be cast-off to make a decision. “There is no one feature or factor which can singlehandedly prompt intervention”. Other standard markers, such as Gleason score, a measure of a cancer’s degree of disorganization, must also be used.